Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 10/20 | 0.45 |
| ▸ | CYP26A1 | O43174 | 6/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582539 | 1.00 | MIF (0.45) | MIFCYP26A1MAOBACHEPTGS2 | |
| SCHEMBL5582796 | 1.00 | MIF (0.45) | MIFCYP26A1MAOBACHEPTGS2 | |
| SCHEMBL7655099 | 0.94 | MIF (0.41) | MIFCYP26A1MAOBACHEPTGS2 | |
| SCHEMBL7655105 | 0.94 | MIF (0.41) | MIFCYP26A1MAOBACHEPTGS2 | |
| SCHEMBL7677769 | 0.84 | CYP26A1 (0.34) | MIFCYP26A1ACHEBCHE | |
| SCHEMBL7677763 | 0.84 | KDM4E (0.40) | MIFCYP26A1MAOBACHEPTGS2 | |
| SCHEMBL7655111 | 0.84 | KDM4E (0.40) | MIFCYP26A1MAOBACHEPTGS2 | |
| SCHEMBL5583024 | 0.83 | MIF (0.48) | MIFCYP26A1MAOBACHEPTGS2 | |
| SCHEMBL5582959 | 0.83 | MIF (0.48) | MIFCYP26A1MAOBACHEPTGS2 | |
| SCHEMBL5582960 | 0.83 | MIF (0.48) | MIFCYP26A1MAOBACHEPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
| EP-1218336-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021577-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | MIF 2071/4885CYP26A1 221/4885MAOB 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.